You know an urban neighborhood is up and coming when it gets an abbreviation like “SoMa,” for the district south of Market Street in San Francisco. So it goes, apparently, with emerging sciences like synthetic biology, which Eleonore Pauwels, a public policy expert who studies the subject, often refers to as “synbio.”
Buzzwords are not all, however.
In a report released Wednesday by the Woodrow Wilson International Center for Scholars, a nonpartisan research institute in Washington, DC, Pauwels and co-authors say that newspaper coverage of synthetic biology, which involves the design and construction of novel life forms, is on the rise on both sides of the Atlantic. The number of articles published between 2008-2011 was almost three times higher than in the preceding four-year period, and it was roughly six times higher, in aggregate, across six European countries (Germany, the UK, France, Italy, Spain, and the Netherlands).
“The main question underlying synbio is, what does it mean to live in a world where humans are creating life—where they are actually synthesizing life? It’s a huge question, so I’m not surprised there is an increase in coverage,” says Pauwels.
The climb started in 2003, but synthetic biology has “burst onto the mainstream” since 2008, according to the report, and three events, in particular, drove headlines. In January 2008, scientists at the J. Craig Venter Institute announced that they had constructed the first synthetic genome and, in May 2010, the same team reported that it had created the first synthetic cell by inserting a manmade genome into a bacterium and activating the manmade DNA. Following the second announcement, President Obama asked his bioethics commission to study the implications of the rapidly progressing research and offer recommendations for oversight and regulation of synthetic biology.
With progress comes scrutiny, and that’s been reflected in the media. More attention has brought a greater focus on the ethical issues and risks associated with synthetic biology, especially in Europe. “American press coverage still emphasized the benefits of synthetic biology but is less rosy than it was between 2003 and 2008,” according to the Wilson Center’s report, and while biosafety and biosecurity are the most popular pegs for articles in the US, ethics is now a close third. The potential payoffs of synthetic biology are still front-and-center in a lot articles, however.
“What’s of interest is that synbio is a revolution in manufacturing,” Pauwels says. “It’s a new way of doing the economy. It’s the molecular economy. You’re going to produce bio-value—new ways to produce everything from plastics, to fuels, to medicines. That’s a really interesting narrative to use in this time of economic crisis, and it’s something you can sell as a growth engine.”
Energy and health products are the most common applications described in the press, but with synthetic biology still in an early stage of development, coverage in the US and Europe continues to focus on studies at universities and research institutes rather than companies and commercial enterprise, though attention to the latter is growing.
Thankfully, since 2008, the American media have presented a more balanced account of the potential risks and benefits of various pursuits in the field, bringing the coverage more in line with the “precautionary” variety found in Europe.
“Articles are more nuanced, so there is an improvement that way,” Pauwels says.
But hype is still a problem, she adds. For instance, a feature article published in May by The New York Times Magazine reported that the designer microbes being developed by J. Craig Venter, the mastermind behind the eponymous, news making institute, “might save the world.”
“You have a lot of storytelling that’s nice to read,” says Pauwels, “but it conveys a lot promise that you probably should not make at this point of the research.”
Part of the problem is language. Pauwels is working on a paper, to be published next year, about the use of metaphors in the coverage of synthetic biology. From Legos to “biobricks” there is “extensive use” of engineering metaphors, in particular, she says. Often coined by scientists and industry, these terms bleed into the press and foster a narrative of safety and control.